Completed PHASE2 INTERVENTIONAL 1-arm NCT01050907

Miltefosine to Treat Mucocutaneous Leishmaniasis

Treatment of Mucocutaneous Leishmaniasis With Miltefosine

Sponsor: Knight Therapeutics (USA) Inc

Conditions Cutaneous Leishmaniasis Mucosal Leishmaniasis

Interventions Miltefosine

Updated 10 times since 2017 Last updated: Sep 8, 2020 Started: May 31, 2010 Primary completion: Feb 28, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cutaneous Leishmaniasis and Mucosal Leishmaniasis, this trial is completed. The trial is conducted by Knight Therapeutics (USA) Inc and has accumulated 10 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Oct 2020 — Jan 2021 [monthly]

Completed PHASE2
Apr 2019 — Oct 2020 [monthly]

Completed PHASE2
Jun 2018 — Apr 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Knight Therapeutics (USA) Inc

Data source: Knight Therapeutics (USA) Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States